The synthesis of a series of 9-ethyladenine derivatives bearing alkynyl chains in 2-or 8-position was undertaken, based on the observation that replacement of the sugar moiety in adenosine derivatives with alkyl groups led to adenosine receptor antagonists. All the synthesized compounds were tested for their affinity at human and rat A 1 , A 2A , and A 3 adenosine receptors in binding assays; the activity at the human A 2B receptor was determined in adenylyl cyclase experiments. Biological data showed that the 2-alkynyl derivatives possess good affinity and are slightly selective for the human A 2A receptor. The same compounds tested on the rat A 1 and A 2A subtypes showed in general lower affinity for both receptors. On the other hand, the affinity of the 8-alkynyl derivatives at the human A 1 , A 2A , and A 2B receptors proved to be lower than that of the corresponding 2-alkynyl derivatives. On the contrary, the affinity of the same compounds for the human A 3 receptor was improved, resulting in A 3 selectivity. As in the case of the 2-alkynyl-substituted compounds, the 8-alkynyl derivatives showed decreased affinity for rat receptors. However, it is worthwhile to note that the 8-phenylethynyl-9-ethyladenine was the most active compound of the two series (K i in the nanomolar range) at both thehuman and rat A 3 subtype. Docking experiments of the 2-and 8-phenylethynyl-9-ethyladenines, at a rhodopsin-based homology model, gave a rational explanation of the preference of the human A 3 receptor for the 8-substituted compound.
Introduction
Adenosine is an autacoid involved in the regulation of many aspects of cellular metabolism [1] and mediates its effects through the activation of at least four human receptors (P1), belonging to the superfamily of G proteincoupled receptors, which have been recently cloned [2] and classified as A 1 , A 2A , A 2B , and A 3 [3] . All subtypes have been cloned from a variety of species including the rat and human. Species differences for the A 3 adenosine receptor (AdoR) are larger than for other AR subtypes, particularly between rodent and human receptors (only 74% sequence identity between rat and human A 3 amino acid sequence) [4] . This results in different affinities of ligands Y particularly antagonists Y for rat versus human A 3 receptors [5, 6] . During the past decades many efforts have been directed toward the discovery of potent and selective adenosine receptor ligands aimed at finding novel drugs [7] .
Most adenosine agonists possess a structure very close to that of the natural ligand adenosine; in contrast a wide range of structural classes have been characterized as adenosine receptor antagonists and developed as potential therapeutic agents for CNS disorders, inflammatory diseases, asthma, kidney failure and ischaemic injuries [8] .
However, only a few xanthine antagonists as caffeine and theophylline have been approved as drugs for their CNS stimulating, diuretic, and bronchodilating effects, respectively [8, 9] .
In many papers it has been demonstrated that introduction of alkynyl chains in the 2-position of adenosine derivatives led to compounds endowed with high affinity at all adenosine receptors (AdoRs) [10Y15] , whereas the introduction of the same alkynyl chains in the 8-position resulted in 8-alkynyladenosines, which were unable to stimulate [
35 S]GTPgS binding, and inhibited that stimulated by NECA, yielded A 3 antagonists [16, 17] .
Moreover, we have published the synthesis and activities for the human AdoR subtypes of a series of 9-ethyladenines, substituted at the 2-, 6-and 8-positions, which behaved as AdoR antagonists [18Y20] . In fact, replacement of the sugar moiety of adenosine with a methyl group led to a rather unselective antagonist of AdoR and adenine itself is a weak adenosine antagonist [21] .N 6 -cyclopentyladenine derivatives were characterized as neutral antagonists endowed with high affinity for the A 1 AdoR [23] .
Hence, starting from these observations and in order to widen our study on 9-ethyladenine derivatives, a series of 9-ethyladenines bearing alkynyl chains at the 2-or 8-position were synthesized and tested at human and rat AdoR subtypes.
Materials and methods

Chemistry
Synthesis of the 2-and 8-alkynyl-9-ethylpurines 2Y10, 12Y19, and 22 The synthesis of the 2-alkynyl-9-ethyladenines 2Y10 and 8-alkynyl-9-ethyladenines 12Y19, was carried out starting from 2-iodo-9-ethyladenine (1; [18] or 8-bromo-9-ethyladenine (11; [18] ), respectively, and are reported in Schemes 1 and 2. In order to obtain the final products compound 1 or 11 was reacted with the suitable terminal alkynes using a modification of the palladium catalyzed cross-coupling reaction [18] .
However, for the synthesis of the 8-alkynyl derivative 22, 8-iodo-9-ethyladenine (21), obtained through the iodination of the 9-ethyladenine (20) [18] with iodine and lithiumdiisopropylamide (LDA), was used as the starting material.
This choice was due to the fact that reaction of 8-bromo-9-ethyladenine (11) with (R,S)-phenylhydroxypropyne failed to give the corresponding 8-phenylhydroxypropynyl analogue, while the reaction was successful when the 8-iodo analogue was used as starting material.
The synthesis of the derivatives 3, 9, 13, and 19 has been already published [18] .
General synthetic procedures
Melting points were determined with a Büchi apparatus and areuncorrected. 1 General method for the synthesis of the 2-or 8-(ar)alkynyl-9-ethyladenines 2, 4Y8, 10, 12, 14Y18 and 22 To a solution of 1, 11 or 21 (0.84 mmol) in dry DMF and CH 3 CN [15 ml (1:2)], bis(triphenylphosphine)palladium dichloride (12 mg, 0.017 mmol) and CuI (0.84 mg, 0.004 mmol), Et 3 N (3.4 ml), and the appropriate terminal alkyne (4.2 mmol) were added. The reaction mixture was stirred under an atmosphere of N 2 at room temperature for the time reported for each compound. The solvent was removed in vacuo and the residue was chromatographed on a silica gel column or TLC plates eluting with a suitable mixture of solvents to give the desired derivatives 2, 4Y8, 10, 12, 14Y18 and 22.
9-Ethyl-2-pent-1-ynyl-9H-purin-6-ylamine (2) . 2-Cyclohex-1-enylethynyl-9-ethyl-9H-purin-6-ylamine (6) . The reaction of 1 with 1-ethynylcyclohexene for 20 h, followed by chromatography on a silica gel column eluting 9-Ethyl-2-phenylethynyl-9H-purin-6-ylamine (7). The reaction of 1 with 1-phenylacetylene for 6 h, followed by chromatography on a silica gel column eluting with CH 2 Cl 2 YCH 3 OH (99.5:0.5), gave, after crystallization from EtOH, 7, as white crystals. Yield 85%, m.p. 250 -C (dec); 1 9-Ethyl-8-pent-1-ynyl-9H-purin-6-ylamine (12) . The reaction of 11 with 1-pentyne for 48 h, followed by chromatography on a silica gel column eluting with CHCl 3 YCH 3 OH (98:2), gave, after crystallization from MeOH, 12, as white crystals. Yield 73%, m.p. 182Y184 -C; 6-(6-Amino-9-ethyl-9H-purin-8-yl)-hex-5-yn-1-ol (14) . The reaction of 11 with 5-hexynyl-1-ol for 48 h, followed by chromatography on a silica gel column eluting with CHCl 3 3-(6-Amino-9-ethyl-9H-purin-8-yl)-1-phenyl-prop-2-yn-1ol (22) . The reaction of 21 with (R,S)-1-phenyl-2-propyn-1-ol for 36 h, followed by chromatography on a silica gel column eluting with CHCl 3 Y CH 3 OH (96:4), gave, after crystallization from CH 3 9-Ethyl-8-iodo-9H-purin-6-ylamine (21) To a solution of 2.2 ml (15.7 mmol) of freshly distilled diisopropylamime and 6.0 ml of dry THF, in a three necked round bottom flask, under a flux of N 2 , were added dropwise 9.8 ml (15.7 mmol) of butyllithium (1.6 M in hexane). The mixture was kept under stirring at r.t. for 15 min. After that, the mixture was cooled at j70 -C and 500 mg (3.1 mmol) of 20, dissolved in 10 ml of dry THF, were added, and after 1 h a solution of iodine (4.9 mmol) in 10 ml of dry THF was added dropwise.
After 1 h more at j70 -C 4 drops of glacial acetic acid and 3 ml of methanol were added. The mixture was allowed to warm at r. t., the solvent was removed in vacuo and the residue was chromatographed on a silica gel column eluting with 
Biological evaluation
Binding studies and adenylyl cyclase activity at human adenosine receptors The radioligand binding experiments were carried out exactly as described previously [24] . For A 1 adenosine receptor binding 1 nM [
3 H]CCPA was used as a radioligand, whereas 30 and 10 nM [ 3 H]NECA was used for A 2A and A 3 receptors, respectively. Non specific binding was determined in the presence of 1 mM theophylline (A 1 ) or 100 mM R-PIA (A 2A and A 3 ). K i values were calculated from competition curves by nonlinear curve fitting with the program SCTFIT [25] . CHO cells stably transfected with human adenosine receptors were grown adherently and maintained in Dulbecco's Modified Eagles Medium with nutrient mixture F12 (DMEM/F12) without nucleosides, containing 10% fetal calf serum, penicillin (100 U/ml), streptomycin (100 mg/ml), L-glutamine (2 mM) and Geneticin (G-418, 0.2 mg/ml) at 37 -C in 5% CO 2 /95% air as described earlier [24] .
For radioligand binding studies and measurement of adenylyl cyclase activity crude membrane fractions were prepared from fresh or frozen cells with two different protocols which were described recently [24] .
Determination of adenylyl cyclase activity followed the procedure described by [24] . IC 50 values for the inhibition of cyclase stimulated with 5 mM NECA were calculated with the Hill equation and converted to K i values with the Cheng and Prusoff equation [24] . The Hill slopes were near unity suggesting a competitive interaction of the antagonists tested. 25 -C. Non-specific binding was determined in the presence of 50 mM R-PIA and accounted to 30% of total binding. Binding reaction was terminated by rapid filtration through a Whatman GF/C filter, washing three times with 5 ml of ice-cold buffer.
Binding studies at rat adenosine receptors
All compounds were routinely dissolved in DMSO and diluted with assay buffer to the final concentration, where the amount of DMSO never exceeded 2%. At least 6 different concentrations of each compound were used and IC 50 values were computer-generated using nonlinear regression formula on a computer program (GraphPad, San Diego, CA 
Molecular modeling studies
All the calculations were carried out utilizing the HyperChem 7.2 program (Hypercube, Gainesville, Florida, USA). For molecular mechanics calculations the AMBER 96 [28] force field was utilized with a distance-dependent dielectric constant scaled by a factor of 4. All the energy minimizations were carried out employing the PolakYRibiere conjugate gradient. All molecular dynamics simulations were carried at a constant temperature of 298 K, using a timestep of 1 fs. Before the simulation, the system, virtually at 0 K, was slowly (1 ps) heated until it reached the simulation temperature.
The human A 3 model used for the docking experiments was the rhodopsin-based homology model previously constructed by us [17] .
2-Phenylethynyl-9-ethyladenine (7) and 8-phenylethynyl-9-ethyladenine (17) were docked into the receptor helical bundle by modifying the ligands in A 3 /2-phenylethynyladenosine or A 3 /8-phenylethynyladenosine complex [17] , respectively.
After applying a harmonic restraint of 7 kcal/mol to the backbone atoms of the protein, the receptor/ligand complexes were submitted to energy minimization (RMS G 0.5 kcal/mol/Å ), 10 ps of molecular dynamics, and energy minimization (RMS G 0.001 kcal/mol/Å ).
Results and discussion
Binding studies
All the compounds were evaluated at the human recombinant adenosine receptors, stably transfected into Chinese hamster ovary (CHO) cells, utilizing radioligand binding studies (A 1 , A 2A , A 3 ) The compounds were also tested for their affinity at rat cortex A 1 , rat striatum A 2A , and rat testis A 3 subtypes, using K i values are in mM with 95% confidence intervals in parentheses. The results are shown in Table 1 .
Biological data showed that the 2-alkynyl derivatives possess good affinity at all human adenosine receptors and are slightly selective for the A 2A subtype.
Compounds 5 and 10 bearing a cyclohexylethyne and a phenylhydroxypropyne in 2-position, respectively, resulted in the most active of the series with K i in the low nanomolar range both at human A 1 and A 2A receptors (5; K i A 1 = 0.080 mM, K i A 2A = 0.037 mM, and 10;
At the A 2B receptor the derivatives bearing linear chains in 2-position showed functional activity in the mM range (2; K i A 2B = 17 mM, 3; K i A 2B = 12 mM, and 4; K i A 2B = 19 mM), while the presence of sterically hindered substituents in the same position was detrimental for the activity. However, the presence of a phenylhydroxypropynyl chain seems to facilitate the interaction with the A 2B subtype, in fact the 2-phenylhydroxypropynyl-9-ethyladenine resulted the most active compound of the two series (10; K i A 2B = 1.4 mM). This finding is in agreement with our previous results obtained with the corresponding adenosine derivative. In fact, the (R,S)-2-phenyhydroxypropynyl-Nethylcarboxamidoadenosine [(R,S)-PHPNECA, EC 50 A 2B = 1.1 mM] resulted in one of the most potent agonist with nucleoside structure at human A 2B receptors reported so far [14, 29] .
The affinity of the 2-alkynyl derivatives for the A 3 subtype was lower than that at A 1 and A 2A receptors.
The same compounds, tested on the rat A 1 and A 2A subtypes, showed in general lower affinity for the rat A 2A receptor, while compounds 7Y9, bearing an aromatic ring in the 2-position, showed slightly higher affinity at the rat A 1 receptor, compared to the corresponding human receptor, hence resulting slightly A 1 selective (7; K i A 1 (r) = 0.43 mM vs K i A 1 (h) = 0.77 mM, 8; K i A 1 (r) = 1.9 mM vs K i A 1 (h) = 8.3 mM, and 9; K i A 1 (r) = 0.15 mM vs K i A 1 (h) = 0.21 mM,). As in the case of human receptors, compounds 5 and 10 showed the highest affinity both at rat A 1 and A 2A subtypes (5; K i A 1 = 0.072 mM, K i A 2A = 0.069 mM, and 10; K i A 1 = 0.14 mM, K i A 2A = 0.14 mM).
At the rat A 3 receptor these compounds showed comparable affinity to that at human one.
As far as the 8-alkynyl derivatives, their affinity at the human A 1 , A 2A , and A 2B receptors proved to be lower than However, it is worthwhile to note that the derivatives, which showed some activity at the A 2B receptor, are those bearing linear chains in the 8-position, as in the case of the 2-substituted compounds (12; K i A 2B = 2.7 mM, 13; K i A 2B = 22 mM, and 14; K i A 2B = 21 mM).
On the contrary, the affinity of the 8-alkynyl derivatives for the human A 3 receptor, compared to the corresponding 2-substituted derivatives, was improved; hence the 8-phenylethynyl-9-ethyladenine (17) with a K i A 3 (h) of 0.086 and 0.25 mM (r) resulted the most active compound of the two series at both the human and rat A 3 subtype and was A 3 selective.
As in the case of the 2-substituted compound, the 8-alkynyl derivatives showed decreased affinity for rat receptors. The selectivity of this series of derivatives for the A 1 , A 2A , and A 3 receptor subtypes was strictly correlated to the nature of the alkynyl chain, and there is a good correlation between affinity at human and rat receptors.
Molecular modeling
In order to get an insight into the mechanism of the ligand recognition and to give a rational explanation of the preference of the human A 3 receptor for the 8-substituted compounds rather than the 2-substituted compounds in this series, we carried out docking experiments of 2-phenylethynyl-9-ethyladenine (7) and 8-phenylethynyl-9-ethyladenine (17) at a rhodopsin-based homology model of the receptor (Figure 1) .
In a previous molecular modeling study [17] , we proposed that 2-and 8-alkynyl derivatives of adenosine bind to the human A 3 receptor in a way that the C2 of a molecule matches the C8 of the other one, with a good steric and electrostatic overlap of the purine moieties and the alkynyl chains.
On the basis of the structure activity relationships data, we hypothesized a similar binding mode for the alkynyl derivatives of adenosine and the correspondent 9-ethyladenine analogues. The results of our docking experiments were in good agreement with the biological data, confirming the soundness of the hypothesis on which they were based.
In the case of the adenosine derivatives, the compounds substituted at the 2-position were endowed with higher affinity than the correspondent 8-substituted analogues. In fact, in the latter case the sugar moiety had unfavourable interactions with the receptor.
On the other hand, in the case of the 2-and 8-phenylethynyl-9-ethyladenine, due to the substitution of the ribose moiety with the less bulky ethyl group, the negative ligand receptor interactions were eliminated even in the case of the 8-substituted compound. According to the results of the present study, in both situations the ethyl group is accommodated in the hydrophobic pocket formed by Leu 90 and Leu 91 of the third transmembrane domain (TM3). Furthermore, the binding of the 8-alkynyl derivative to the A 3 receptor appears to be facilitated by a stronger electrostatic interaction of the crucial Asn 250 (TM6) with the adenine ring compared to the case of the 2-alkynyl derivatives (Figure 1 ).
Conclusions
With this study we have demonstrated that it is possible to modulate the activity at the adenosine receptor subtypes by introducing alkynyl chains in the 2-or 8-position of the 9-ethyladenine.
Although all the synthesized compounds were more active at human receptors, it is worthwhile to note that, in the series of the 2-substituted derivatives, compounds 5 and 10 are the ones endowed with the highest affinity at both human and rat A 1 and A 2A receptors.
The same trend has been observed with the 8-substituted derivatives: in fact the 8-phenylethynyl-9-ethyladenine (17) proved to be the most active and selective compound of the two series at human and rat A 3 subtype.
From these results it is possible to conclude that the selectivity of these two series of derivatives for the A 1 , A 2A , and A 3 receptor subtypes is strictly correlated to the nature of the alkynyl chain, and that there is a good correlation between the affinity at human and rat receptors.
